7-甲基-1H-吡唑并[4,3-b]吡啶 | 1130309-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 7-甲基-1H-吡唑并[4,3-b]吡啶
• 中文别名: 7-甲基-4-氮杂吲唑
• 英文名称: 7-Methyl-1H-pyrazolo[4,3-b]pyridine
• CAS: 1130309-70-4
• 化学式: C₇H₇N₃
• 分子量: 133.15
• InChiKey: MFQZVNXIXXFCKR-UHFFFAOYSA-N

物化性质

• 沸点：
  308.2±22.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
  申请人：INTEGRAL BIOSCIENCES PVT LTD

  公开号：WO2020012357A1

  公开（公告）日：2020-01-16

  The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type 1 or activin-like kinase 5 (ALK 5). Specifically the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

  本发明揭示了在治疗与转化生长因子β（TGF-β）过度活性相关的疾病中有用的化合物，特别是针对类型1或类活化激酶5（ALK 5）。具体来说，本发明揭示了具有对ALK 5具有抑制活性的化合物的结构式（I）。还公开了使用这种化合物治疗与过度活性（ALK 5）相关的疾病的方法。此外，还公开了这些化合物的用途、制药组合物和试剂盒。
• Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction
  申请人：Conn P. Jeffrey

  公开号：US20130065895A1

  公开（公告）日：2013-03-14

  Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

  Pyrazolopyridine，pyrazolopyrazine，pyrazolopyrimidine，pyrazolothiophene和pyrazolothiazole化合物，可作为代谢型谷氨酸受体亚型4（mGluR4）的变构势增强剂/正变构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物的方法，例如用于治疗神经和精神障碍或与谷氨酸功能障碍相关的其他疾病状态。
• POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR
  申请人：Hangzhou Innogate Pharma Co., Ltd.

  公开号：EP3686196A1

  公开（公告）日：2020-07-29

  The present invention provides polycyclic compounds as IDO inhibitors and/or dual inhibitors of IDO-HDAC. Specifically, the present invention provides compounds represented by the following formula (I), wherein each group is defined as described in the specification. The compounds have IDO inhibitory activity or IDO-HDAC dual inhibitory activity and can be used for preventing or treating diseases associated with IDO and/or IDO-HDAC activity or expression levels. At the same time, the compounds of the present invention can be combined with an antitumor antibody such as PD-1 and PD-L1, and such a combination can greatly increase the antitumor response rate of the antibody and broaden the types of tumors to be treated.

  本发明提供了作为 IDO 抑制剂和/或 IDO-HDAC 双重抑制剂的多环化合物。具体而言，本发明提供了由下式（I）代表的化合物，其中各基团的定义如说明书所述。这些化合物具有 IDO 抑制活性或 IDO-HDAC 双重抑制活性，可用于预防或治疗与 IDO 和/或 IDO-HDAC 活性或表达水平相关的疾病。同时，本发明的化合物可以与抗肿瘤抗体如 PD-1 和 PD-L1 结合使用，这样的结合可以大大提高抗体的抗肿瘤反应率，扩大治疗肿瘤的种类。
• SUBSTITUTED INDOLE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210253593A1

  公开（公告）日：2021-08-19

  Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R 1 , R 2 , R 3 , R 4 , R 5 , m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.